OncoMed Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘OncoMed Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the OncoMed Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by OncoMed Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of OncoMed Pharmaceuticals, Inc.

The report provides overview of OncoMed Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses OncoMed Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features OncoMed Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate OncoMed Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for OncoMed Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding OncoMed Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

OncoMed Pharmaceuticals, Inc. Snapshot 6

OncoMed Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

OncoMed Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

OncoMed Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

OncoMed Pharmaceuticals, Inc. - Pipeline Products Glance 14

OncoMed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

OncoMed Pharmaceuticals, Inc. - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

OncoMed Pharmaceuticals, Inc. - Drug Profiles 17

demcizumab 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

tarextumab 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

brontictuzumab 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ipafricept 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

OMP-131R10 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

OMP-305B83 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

vantictumab 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

IO-2 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

IO-3 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody to Agonize GITR for Oncology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody to Inhibit Hippo Pathway for Cancer 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

OncoMed Pharmaceuticals, Inc. - Pipeline Analysis 37

OncoMed Pharmaceuticals, Inc. - Pipeline Products by Target 37

OncoMed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 38

OncoMed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 39

OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 40

OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates 41

OncoMed Pharmaceuticals, Inc. - Dormant Projects 61

OncoMed Pharmaceuticals, Inc. - Discontinued Pipeline Products 62

Discontinued Pipeline Product Profiles 62

brontictuzumab 62

tarextumab 62

OncoMed Pharmaceuticals, Inc. - Locations And Subsidiaries 63

Head Office 63

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

List of Tables

OncoMed Pharmaceuticals, Inc., Key Information 6

OncoMed Pharmaceuticals, Inc., Key Facts 6

OncoMed Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

OncoMed Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

OncoMed Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

OncoMed Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

OncoMed Pharmaceuticals, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

OncoMed Pharmaceuticals, Inc. – Phase II, 2016 14

OncoMed Pharmaceuticals, Inc. – Phase I, 2016 15

OncoMed Pharmaceuticals, Inc. – Preclinical, 2016 16

OncoMed Pharmaceuticals, Inc. – Pipeline by Target, 2016 37

OncoMed Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 38

OncoMed Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 39

OncoMed Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 40

OncoMed Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 41

OncoMed Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 61

OncoMed Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 62

List of Figures

List of Figures

OncoMed Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

OncoMed Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

OncoMed Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

OncoMed Pharmaceuticals, Inc. – Pipeline by Target, 2016 37

OncoMed Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 38

OncoMed Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 39

OncoMed Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 40

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports